TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
about
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineTIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.Mechanisms regulating resistance to inhibitors of topoisomerase II.Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinica
P2860
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
TIMP-1 in combination with HER ...... h-risk breast cancer patients.
@en
type
label
TIMP-1 in combination with HER ...... h-risk breast cancer patients.
@en
prefLabel
TIMP-1 in combination with HER ...... h-risk breast cancer patients.
@en
P2093
P2860
P1476
TIMP-1 in combination with HER ...... h-risk breast cancer patients.
@en
P2093
Annette Bartels
Dongsheng Tu
Eva Balslev
Frances P O'Malley
Kathleen I Pritchard
Lois E Shepherd
Maj-Britt Jensen
Nils Brünner
Pernille Braemer Hertel
Shan Jiang
P2860
P2888
P304
P356
10.1007/S10549-011-1896-1
P407
P577
2011-12-09T00:00:00Z
P6179
1001912057